Dr Dennis Carney
Clinical Supervisor
Department of Medical Education
88 Scholarly works
0 Projects
HIGHLIGHTS
2025
Journal article
Impact of prognostic mutations on outcomes with fixed-duration acalabrutinib-venetoclax combinations versus chemoimmunotherapy: An exploratory analysis from AMPLIFY
DOI: 10.1182/blood-2025-38982025
Journal article
Continuous venetoclax for relapsed chronic lymphocytic leukemia (CLL) – characteristics and outcomes of long-term responders
DOI: 10.1182/blood-2025-21302025
Journal article
HAT-PCR Enables Sensitive Quantification of Minimal Residual Disease in Chronic Lymphocytic Leukemia and Myeloma
DOI: 10.3390/ijms261677202025
Journal article
Final analysis of fixed-duration ibrutinib venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in the phase 2 CAPTIVATE study.
DOI: 10.1200/jco.2025.43.16_suppl.70362022
Journal article
Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL
DOI: 10.1182/blood.20210127752015
Journal article
Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20 lymphoid malignancies
DOI: 10.1111/bjh.134872012
Journal article
Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: Results of a phase I study of navitoclax in patients with relapsed or refractory disease
DOI: 10.1200/JCO.2011.34.7898
RECENT SCHOLARLY WORKS
2025
Journal article
71 | FINAL ANALYSIS OF FIXED‐DURATION IBRUTINIB VENETOCLAX FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL) IN THE PHASE 2 CAPTIVATE STUDY
DOI: 10.1002/hon.70093_712024
Journal article
Consistently High 5.5-Year Progression-Free Survival (PFS) Rates in Patients with and without Bulky Baseline Lymphadenopathy ≥5 Cm Are Associated with High Undetectable Minimal Residual Disease (uMRD4) Rates after First-Line Treatment with Fixed-Duration Ibrutinib Venetoclax for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) in the Phase 2 CAPTIVATE Study
DOI: 10.1182/blood-2024-2009362024
Journal article
Outcomes in High-Risk Subgroups After Fixed-Duration Ibrutinib (Ibr) Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Up to 5.5 Years of Follow-Up in the Phase 2 CAPTIVATE Study
DOI: 10.1016/s2152-2650(24)00564-02024
Conference Proceedings
Outcomes in High-Risk Subgroups After Fixed-Duration Ibrutinib (Ibr) plus Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Up to 5.5 Years of Follow-Up in the Phase 2 CAPTIVATE Study
DOI: 10.1016/s2152-2650(24)01258-82024
Journal article
Outcomes in high-risk subgroups after fixed-duration ibrutinib plus venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Up to 5.5 years of follow-up in the phase 2 CAPTIVATE study
DOI: 10.1200/jco.2024.42.16_suppl.70092022
Conference Proceedings
Shielding the Vulnerable: A Multicentre Australian Rollout of Evusheld to Patients with Chronic Lymphocytic Leukaemia (CLL-SHIELD)
DOI: 10.1182/blood-2022-165609